TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 23:56 · $VIAGEN · Colossal acquires Viagen for 80% cloning efficiency vs 2% industry standard
episode briefing
Sourcery VC

$12B De-Extinction Company Colossal Biosciences Spun Out $3.8B Astromech

2026-08-20 · 7 company · 14 thematic
sentiment
7 bull0 bear0 neu
speakers
ben lamm

Serial entrepreneur with multiple successful exits; founded Colossal Biosciences to pursue de-extinction and genome engineering at planetary scale; previously built satellite and imaging companies with defense connections.

quote
“Vioagen had like cloning efficiencies at 80% where most people are at 2% right and so it made sense for us to say okay we need to buy them and bolt them on from a vertical integration perspective.”
—ben lamm

episode shorts · 1

Woolly Mice, Dire Wolves & a $3.8B AI Spinout: Inside $12B Colo…

now playing · $VIAGEN
$COLOSSAL-BIOSCIENCESbullish· highben lamm
Colossal raises $400M round, 2x oversubscribed, plans more capital
The last $400M round was originally targeted at $200M but was 2x oversubscribed; Lamm says every round has been >2x oversubscribed, signaling strong investor demand and that the c…
$COLOSSAL-BIOSCIENCESbullish· highben lamm
Lamm calls Colossal one of world's most undervalued companies after $400M oversubscribed round
Colossal's vertical integration across genome engineering, artificial wombs, and DNA synthesis at planetary scale creates a civilization-tech platform with applications from de-ex…
$COLOSSAL-BIOSCIENCESbullish· highben lamm
Colossal raises $400M at $12B valuation, 2x oversubscribed, plans more capital
Strong investor demand validates the platform; $635M total raised with last round targeting $200M but closing at $400M, and Lamm expects further raises to fund the expanding pipel…
$ASTROMECHbullish· mediumben lamm
Colossal spinout Astromech uses evolutionary AI to find cancer-resistance targets
Astromech applies a focused AI model to evolutionary genomics — leveraging Colossal's massive elephant dataset — to identify conserved cancer-resistance mechanisms (e.g., p53 over…
$VIAGENbullish· mediumben lamm
Colossal acquires Viagen for 80% cloning efficiency vs 2% industry standard
Vertical integration via Viagen acquisition gives Colossal best-in-class cloning infrastructure (80% efficiency vs 2% typical), a critical bottleneck for endangered-species produc…
$COLOSSAL-BIOSCIENCESbullish· highben lamm
Gene-drive screwworm eradication could save taxpayers $1.5B and 8 years vs current plan
Colossal's gene-drive technology can eradicate the New World screwworm in 6-7 months versus the USDA's 8-year, $1.5B chemical program, representing a massive government-contract o…
$COLOSSAL-BIOSCIENCESbullish· highben lamm
Exceeding edit-scale roadmap: hundreds of multiplex edits now, thousands targeted
Technical execution far surpassing early milestones — told 5-7 edits in 5 years would be great, now doing hundreds and pushing a new construct for thousands of simultaneous edits,…